Why Do These Misconceptions Persist?

Despite stringent regulatory compliance norms and training efforts, confusion between shelf life and expiry arises due to overlapping definitions, inconsistent communication, and inadequate function-specific training. These misconceptions are particularly dangerous during labeling, stability data interpretation, and audit responses.

Let’s break down the myths and replace them with evidence-backed facts aligned with global standards like ICH guidelines.

Myth 1: Shelf Life and Expiry Date Are Interchangeable

Reality: Shelf life is the time a drug remains within approved specifications. Expiry date is the final, legally enforceable date a drug can be used. While expiry is derived from shelf life, the terms serve different regulatory and operational purposes.

• Shelf life guides internal stability decisions
• Expiry date is what appears on labels and affects product use

This confusion often leads to errors in documentation and ERP labeling systems.

Myth 2: Expiry Can Be Extended Without Stability Data

Reality: Expiry extension requires robust supporting data—typically, real-time stability results following ICH Q1E guidelines—and prior regulatory approval. Any extension made without submission or justification is a critical GMP violation.

Case example: A company extended expiry to 36 months based on an assumption that data trends would hold. During inspection, USFDA flagged the deviation, resulting in a warning letter.

Myth 3: Beyond Use Date and Expiry Date Are the Same

Reality: Beyond Use Date (BUD) refers to the last date a compounded or reconstituted product can be used. This is different from the manufacturer-set expiry date, which is based on long-term stability studies.

• BUD is shorter and assigned post-opening or compounding
• Expiry is fixed and printed on sealed product packages

Mislabeling BUD as expiry can result in improper usage timelines and miscommunication in clinical trial protocols.

Myth 4: Expiry Date Can Be Calculated Manually for Each Batch

Reality: Expiry date must be derived from validated, documented shelf life and calculated via ERP or other GMP-controlled systems. Manual calculations pose a major risk for inconsistency and labeling errors.

Use of validated electronic systems with locked expiry logic is a best practice in process validation and labeling compliance.

Myth 5: Stability Failures After Expiry Don’t Impact Compliance

Reality: Post-expiry stability failures (even if discovered through internal testing) reflect on the accuracy of originally assigned shelf life and expiry. These must be investigated, reported, and, if needed, used to revise ongoing stability protocols or labeling practices.

Myth 6: Expiry Date Format Is Universal Across All Countries

Reality: While many regulatory bodies prefer the “MM/YYYY” format, others (e.g., certain ASEAN or Latin American countries) require “DD/MM/YYYY” or “Month Year” textual formats. Failing to comply with local standards can lead to market-specific non-compliance.

• Always cross-check with regional regulatory labeling guidelines
• Implement artwork variations per country submission
• Audit all language versions for consistency

Myth 7: Recalled Products Can Be Re-labeled with New Expiry

Reality: Relabeling recalled drugs with a new expiry without appropriate regulatory approval and fresh stability data is a GMP breach. In most jurisdictions, recalled lots cannot be reused or re-labeled unless stability integrity and traceability are demonstrated.

Proper change control and documentation are essential before any re-issuance or relabeling.

Addressing Misconceptions Through Training

Dispelling these myths requires structured, ongoing training programs across departments:

• Monthly refresher trainings on labeling and expiry handling
• Department-specific quizzes to evaluate understanding
• Use of real case studies from warning letters and audits
• Simulation exercises involving mock recalls or labeling reviews

Integrating such initiatives within the pharma organization improves long-term compliance outcomes.

Checklist to Combat Shelf Life and Expiry Myths

• Include definitions in all GMP and labeling SOPs
• Maintain change logs for expiry updates in ERP
• Implement dual verification for expiry calculations
• Include expiry validation in annual product review
• Align artwork approval with regulatory filings

Regular checklist use prevents assumptions from entering critical processes like labeling, stability testing, and market release.

Conclusion

In the pharmaceutical industry, where precision is paramount, misconceptions about shelf life and expiry date can have serious consequences—from product recalls to patient risk. Educating teams, using validated systems, and maintaining cross-functional alignment are key strategies for eliminating these myths.

By recognizing common misunderstandings and proactively correcting them, pharma companies can ensure better SOP training, improved regulatory trust, and stronger internal compliance frameworks.

References:

• ICH Q1A and Q1E Guidelines
• FDA Stability Testing
• CDSCO India Labeling Guidance
• EMA Stability Guidance